Eli Lilly (LLY) Down on Convction Sell, Merck (MRK) Up On Conviction Buy
More News related to LLY
- Trading Review for Vivus Inc. Issued by Beacon Equity
- VerifyNow(R) System Highlighted in POPular Study Comparing Platelet Reactivity Tests
- New Updates to AHA/ACC/SCAI Clinical Guidelines Recommend Treatment with Effient(R) for Patients with Acute Coronary Syndromes Managed with PCI
- Lilly Surpasses United Way 2009 Campaign Goal
- Effient(R) Exhibited Greater Antiplatelet Activity than High Dose Clopidogrel in Type 2 Diabetes Mellitus Patients with Coronary Artery Disease
More News related to MRK
- Merck (MRK) Declares $0.38 Quarterly Dividend; 4.1% Yield; Announces $3B Common Buyback
- Merck Announces Quarterly Dividends and New $3 Billion Share Repurchase Program
- PROLOR Biotech Reports Merck Receives Positive Regulatory Opinion for European Marketing of Long-Acting CTP-Modified Fertility Treatment ELONVA(R) (FSH-CTP)
- PROLOR Biotech Reports Merck Receives Positive Regulatory Opinion for European Marketing of Long-Acting CTP-Modified Fertility Treatment ELONVA(R) (FSH-CTP)
- Merck Wins Summary Judgment in Second Federal Bellwether Case Involving FOSAMAX(R) (alendronate sodium)
More News related to Insiders' Blog
- Research Firm Questions Surge In Origin Agritech (SEED)
- Starbucks (SBUX) Bets Big On China
- Gold Higher On Reports India Could Buy the Rest of the IMF's Hoard (GLD)
- Corning (GLW) Displays Desire to Acquire - WSJ
- Vietnam Devalues Currency, Hikes Rates
Shares of Eli Lilly & Co. (NYSE: LLY) are 3% weaker today after Goldman Sachs added the stock to its dreaded Conviction Sell List earlier today. Shares of rival Merck & Co. Inc. (NYSE: MRK) is seeing the opposite reaction, up 2.4% after being added to the Conviction Buy List at Goldman.
On Eli Lilly, the firm cited concerns about upcoming patent cliff, its thin pipeline and premium valuation.
On Merck, the firm cited a discount valuation and the potential for cost-driven earnings acceleration.
Real-Time Market Moving News Two-Weeks FREE http://www.streetinsider.com/premium_content.php
Related Categories
Insiders' BlogStocks Mentioned
+0.09Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
